Business · 29/10/20261 min read
StimCardio Closes Oversubscribed $30 Million Series A Financing to Advance Wearable Therapeutic for Atrial Fibrillation
Summary
The funding follows the results of a peer-reviewed NeuroPulse pilot study and supports a pivotal trial of RhyviveTM, an investigational adjunctive therapy designed to extend AF treatment beyond hospital and into the home.
Original source language: PR Newswire UK — News ReleasesOpen original release →